Compare Costco Wholesale Corporation (COST) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs Novavax Inc — how do they compare? Costco Wholesale Corporation trades at $946.58 (market cap $420.05B), while Novavax Inc trades at $12.91 (market cap $1.82B). The key difference: Costco Wholesale Corporation is far larger — about 230.8× Novavax Inc's market cap, and Costco Wholesale Corporation pays a 0.62% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Costco Wholesale Corporation for 133 Days and Novavax Inc for 59 Days on average.
| COST | NVAX | |
|---|---|---|
Market Cap | $420.05B | $1.82B |
Volume | 2,087,565 | 6,198,505 |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $12.56 |
52-Week Low | $849.63 | $6.22 |
Typical Hold Time | 133 Days | 59 Days |
Enterprise Value | $407.33B | $1.39B |
Dividend Yield | 0.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COST trades at $944.20, up 0.21% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong March 2026 sales growth of 11.3% year-over-year (Costco Wholesale Corporation, April 8, 2026) and has shown consistent revenue and net income growth, with fiscal 2025 revenue at $275.24B and net income at $8.10B. Analyst consensus is strongly bullish with a $1,100 price target, though valuation ratios like a P/E of 45.66 are elevated.
The outlook remains positive due to robust membership fee growth and expansion, but risks include high valuation sensitivity and competitive pressures. Upside is supported by strong institutional buying and earnings beats, though any market pullback could pressure the stock given its premium multiples.
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
